A multicenter, double-blind, randomized, active controlled study to compare the effect of long term treatment with LAF237 50 mg bid to gliclazide up to 320 mg daily in drug naïve patients with type 2 diabetes

Registry ID

EUCTR2004-000540-24

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Novartis Pharma Services AG

Start date

2004-12-14

Completion date

2008-03-03

Last update

2026-08-16

Conditions

• Type II Diabetes
• Type 2 Diabetes

Summary

Primary objective 1. To demonstrate the efficacy of LAF237 in patients with type 2 diabetes by testing the hypothesis that the HbA1c reduction with LAF237 is not inferior to that with gliclazide after 104 weeks of treatment.

Locations

• , , Denmark
• , , Spain
• , , Ireland
• , , UK
• , , Germany
• , , Italy

Related clinical trials

• NOURISH - A Healthcare-community Partnership to Improve Nutrition for Optimal Glycemic Control and Pregnancy Outcomes With Pregestational Diabetes
• Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
• A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
• Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
• A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
• The GRoceries Aimed at Increasing Nutrition Study

View on source registry